Document is current
Any future updates will be listed below
-
Authors
Kämpe, Anders https://orcid.org/0000-0002-1829-3855
Gudmundsson, Sanna
Walsh, Colum P.
Lindblad-Toh, Kerstin
Johansson, Åsa https://orcid.org/0000-0002-2915-4498
Clareborn, Anna
Ameur, Adam https://orcid.org/0000-0001-6085-6749
Edsjö, Anders https://orcid.org/0000-0001-8783-8284
Fioretos, Thoas
Ehrencrona, Hans https://orcid.org/0000-0002-5589-3622
Eriksson, Daniel https://orcid.org/0000-0001-5473-3312
Fall, Tove https://orcid.org/0000-0003-2071-5866
Franks, Paul W. https://orcid.org/0000-0002-0520-7604
Gyllensten, Ulf https://orcid.org/0000-0002-6316-3355
Haag, Margareta
Hagwall, Anna
Johansson Soller, Maria
Lehtiö, Janne https://orcid.org/0000-0002-8100-9562
Lu, Yi https://orcid.org/0000-0001-9933-3654
Magnusson, Patrik K. E. https://orcid.org/0000-0002-7315-7899
Melén, Erik https://orcid.org/0000-0002-8248-0663
Melin, Beatrice
Michaëlsson, Karl
Nordgren, Ann https://orcid.org/0000-0003-3285-4281
Nordlund, Jessica https://orcid.org/0000-0001-8699-9959
Saal, Lao H. https://orcid.org/0000-0002-0815-1896
Schwenk, Jochen M. https://orcid.org/0000-0001-8141-8449
Sikora, Per
Sundström, Johan https://orcid.org/0000-0003-2247-8454
Taylan, Fulya https://orcid.org/0000-0002-2907-0235
Van Guelpen, Bethany https://orcid.org/0000-0002-9692-101X
Wadelius, Mia https://orcid.org/0000-0002-6368-2622
Wedell, Anna
Wirta, Valtteri https://orcid.org/0000-0003-3811-5439
Östling, Päivi
Jacobsson, Bo https://orcid.org/0000-0001-5079-2374
Sjöblom, Tobias https://orcid.org/0000-0001-6668-4140
Persson, Bengt
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
Lindstrand, Anna https://orcid.org/0000-0003-0806-5602
Lappalainen, Tuuli
- License Information
-
More Information
Article History
First Online: 4 April 2025
Competing interests
: T.F. is co-founder, board member and scientific advisor to Qlucore and Lead Biologics and co-founder and scientific advisor to Cantargia. P.F. is a paid member of advisory boards for Novo Nordisk, Sidra Health, Zoe and ABC Labs; has received research funding (paid to institution) from numerous pharmaceutical companies as part of the Innovative Medicines Initiative of the European Union; and is co-chair of the Precision Medicine in Diabetes Initiative and the US National Institute of Diabetes and Digestive and Kidney Diseases Working Group of Council on Heterogeneity in Diabetes. L.S. is co-founder and shareholder of SAGA Diagnostics and advisor to DoMore Diagnostics and has received honoraria from AstraZeneca. J.S. has conducted contract research (paid to institution) for Capitainer and Luminex and has received speaker/travel fees from Roche Diagnostics, Olink and Luminex. E.M. has received advisory board or lecture honoraria from ALK, AstraZeneca, Chiesi and Sanofi. J.S. has direct or indirect stock ownership in companies (Anagram kommunikation, Sence Research, Symptoms Europe and MinForskning) providing services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma and WeMind. B.V.G. has received speaker honoraria from AstraZeneca. T.S. is co-founder, shareholder and board member of Oncodia. R.R. has received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, Lilly and Roche. A.L. has received speaker honoraria from Illumina and Pacific Biosciences. T.L. is a scientific advisor to and has equity in Variant Bio and has received speaker honoraria from Abbvie and Merck.
